Arcus Biosciences, Inc. (NYSE:RCUS) Receives $33.67 Average PT from Analysts

Arcus Biosciences, Inc. (NYSE:RCUS) has been given an average recommendation of “Buy” by the ten ratings firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $34.13.

A number of research analysts have commented on the stock. Barclays raised their target price on shares of Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a research report on Friday, October 25th. Evercore ISI raised shares of Arcus Biosciences to a “strong-buy” rating in a research report on Friday, August 9th. HC Wainwright restated a “neutral” rating and set a $20.00 price objective on shares of Arcus Biosciences in a research note on Wednesday, November 6th. Wedbush reiterated an “outperform” rating and issued a $36.00 target price on shares of Arcus Biosciences in a research note on Thursday, November 7th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcus Biosciences in a research note on Thursday, October 3rd.

Institutional Trading of Arcus Biosciences

A number of institutional investors have recently modified their holdings of the company. Headlands Technologies LLC purchased a new position in shares of Arcus Biosciences during the 1st quarter valued at approximately $59,000. Innealta Capital LLC acquired a new position in shares of Arcus Biosciences during the second quarter valued at $66,000. Point72 DIFC Ltd acquired a new position in shares of Arcus Biosciences during the second quarter valued at $83,000. Quest Partners LLC boosted its stake in Arcus Biosciences by 40,904.3% during the third quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock valued at $144,000 after buying an additional 9,408 shares in the last quarter. Finally, ProShare Advisors LLC boosted its stake in Arcus Biosciences by 7.4% during the first quarter. ProShare Advisors LLC now owns 10,846 shares of the company’s stock valued at $205,000 after buying an additional 746 shares in the last quarter. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Arcus Biosciences Stock Performance

Shares of NYSE RCUS opened at $17.74 on Thursday. The stock has a market cap of $1.62 billion, a PE ratio of -5.63 and a beta of 0.89. The firm has a fifty day moving average price of $16.62 and a 200-day moving average price of $16.09. Arcus Biosciences has a 1 year low of $12.95 and a 1 year high of $20.31. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.24 and a quick ratio of 5.14.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($1.00) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.06. The business had revenue of $48.00 million during the quarter, compared to analyst estimates of $38.95 million. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. Arcus Biosciences’s quarterly revenue was up 50.0% compared to the same quarter last year. During the same quarter last year, the business earned ($0.94) earnings per share. Equities analysts anticipate that Arcus Biosciences will post -3.25 earnings per share for the current fiscal year.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.